Array publishes Phase 3 data on melanoma combo

Array BioPharma Inc. (NASDAQ: ARRY) today announced the publication of detailed overall survival (OS) results from the COLUMBUS trial in The Lancet Oncology.

The pivotal Phase 3 trial evaluated the efficacy and safety of the combination of BRAFTOVI+ MEKTOVIcompared to vemurafenib monotherapy in patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation. BRAFTOVI + MEKTOVI reduced the risk of death compared to treatment with vemurafenib [hazard ratio (HR) of 0.61, (95% CI 0.47-0.79, p

https://www.marketscreener.com/ARRAY-BIOPHARMA-INC-8433/news/Array-BioPharma-Announces-Publication-of-BRAFTOVI-MEKTOVI-Phase-3-Overall-Survival-Data-in-the-L-27272225/